You are here: Home » Current Affairs » Coronavirus » News
Business Standard

Govt to back phase-3 trials, manufacture of Russian vaccine: NITI Aayog

Aayog member V K Paul said Indian scientists have studied Russian vaccine data and assessed a need for phase-3 trial which can be facilitated by govt as per Indian rules

Topics
Health Ministry | Coronavirus | Lockdown

Ruchika Chitravanshi  |  New Delhi 

coronavirus, coronavirus vaccine
The Serum Institute of India of Pune will also undertake phase-3 trials of the Oxford-AstraZeneca vaccine next week

The Centre is in discussions with Russia to pave the way for phase-3 trials and scale up the manufacture of the Sputnik V vaccine for developed by Moscow-based Gamaleya Institute in India, V K Paul, member-health, said on Tuesday.

“The Government of India attaches great importance to this offer of a partnership from a friend, who is a very special friend to this nation...Outreach has been extended to several companies in India and many have come forward,” he said while addressing a briefing on Covid situation in India.

Paul said that Russia had sought India’s help to scale up manufacturing through the domestic network of vaccine makers and finding a partner to undertake the phase three trial or any bridging study required to take the vaccine forward.

“On both the tracks there has been significant movement. It is a win-win situation for India and the world,” Paul added.

He also said that Indian scientists have studied the Russian vaccine data and assessed a need for a phase three trial which can be facilitated by the government as per the regulatory system of India.

ALSO READ: UNICEF to lead global procurement, supply of coronavirus vaccines

chart

The Serum Institute of India of Pune will also undertake phase-3 trials of the Oxford-AstraZeneca vaccine next week on 1,600 candidates across 17 sites. The Indian company has a capacity to manufacture 75-100 million doses of the vaccine per month, according to the government.

India, now the second highest coronavirus-affected country, has reached a total of 4,280,422 cases and 72,775 deaths. On Monday the country registered 1,133 deaths, highest in a single day since July.

“The numbers have not stabilised, but it is also because we are testing liberally,” Paul said.

While the fatality rate has come down from 2.15 per cent in the first week of August to 1.7 per cent in September, cases per million have risen from 2,792 to 3,102 in the past five days. The global average of cases per million population is 3,527.

The virus has now spread to most parts of the country, including the Andamans and Nicobar Island, where there are 312 active cases so far. has said that tests were conducted among the Onge and Jarawas tribes which are among the particularly vulnerable tribal groups and no negative result was found.

However there are 15 active cases among the Nicobarese people who are a scheduled tribe. Six were found infected among the Great Andamanese but have now recovered.

New vaccine under trial

A new experimental Covid-19 vaccine originating from the University of Oxford has begun human trials in Australia in partnership with the Serum Institute of India. The shot was devised by SpyBiotech, a UK company spun out of Oxford in 2017 by researchers who worked alongside Adrian Hill and Sarah Gilbert at the university’s Jenner Institute. The institute has one of the most advanced Covid-19 shots currently in final-stage trials in partnership with AstraZeneca.Bloomberg

Dear Reader,


Business Standard has always strived hard to provide up-to-date information and commentary on developments that are of interest to you and have wider political and economic implications for the country and the world. Your encouragement and constant feedback on how to improve our offering have only made our resolve and commitment to these ideals stronger. Even during these difficult times arising out of Covid-19, we continue to remain committed to keeping you informed and updated with credible news, authoritative views and incisive commentary on topical issues of relevance.
We, however, have a request.

As we battle the economic impact of the pandemic, we need your support even more, so that we can continue to offer you more quality content. Our subscription model has seen an encouraging response from many of you, who have subscribed to our online content. More subscription to our online content can only help us achieve the goals of offering you even better and more relevant content. We believe in free, fair and credible journalism. Your support through more subscriptions can help us practise the journalism to which we are committed.

Support quality journalism and subscribe to Business Standard.

Digital Editor

First Published: Tue, September 08 2020. 18:59 IST
RECOMMENDED FOR YOU
.